Phase 3 Clinical Trials With Primary Completion Dates in October 2023

This is a list of Phase 3 trials with primary completion dates in October 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
APLMWApollomics, Inc.2023-10-01Phase 3NCT05054543Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
ARDSAridis Pharmaceuticals, Inc.2023-10-01Phase 3NCT05331885A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
BLCOBausch + Lomb Corporation2023-10-01Phase 3NCT05360784"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
CHHEChina Health Industries Holdings, Inc.2023-10-01Phase 3NCT04522102Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase
CORTCorcept Therapeutics Incorporated2023-10-01Phase 3NCT04308590Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
EIGREiger BioPharmaceuticals, Inc.2023-10-01Phase 3NCT04727424Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
ITCIIntra-Cellular Therapies, Inc.2023-10-01Phase 3NCT05061706Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
TNXPTonix Pharmaceuticals Holding Corp.2023-10-01Phase 3NCT05273749A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia